These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7777108)

  • 1. Avoiding acyclovir neurotoxicity in patients with chronic renal failure undergoing haemodialysis.
    Almond MK; Fan S; Dhillon S; Pollock AM; Raftery MJ
    Nephron; 1995; 69(4):428-32. PubMed ID: 7777108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis.
    Stathoulopoulou F; Almond MK; Dhillon S; Raftery MJ
    Nephron; 1996; 74(2):337-41. PubMed ID: 8893152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurotoxicity associated with acyclovir in end stage renal failure.
    Kitching AR; Fagg D; Hay NM; Hatfield PJ; Macdonald A
    N Z Med J; 1997 May; 110(1043):167-9. PubMed ID: 9196501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurotoxicity associated with oral acyclovir in patients undergoing dialysis.
    MacDiarmaid-Gordon AR; O'Connor M; Beaman M; Ackrill P
    Nephron; 1992; 62(3):280-3. PubMed ID: 1436338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acyclovir Neurotoxicity in an Elderly Patient With End-Stage Renal Failure.
    Bełz A; Dębowska P; Głogowska-Szeląg J
    Am J Ther; 2020; 27(5):e525-e527. PubMed ID: 31794437
    [No Abstract]   [Full Text] [Related]  

  • 6. [Severe central nervous system symptoms following oral administration of acyclovir in a patient with chronic renal failure: a case report].
    Niibori D; Fujisawa M; Matsuzaki M
    Hinyokika Kiyo; 1993 May; 39(5):459-61. PubMed ID: 8322628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More about acyclovir neurotoxicity in patients on haemodialysis.
    Gómez Campderá FJ; Verde E; Vozmediano MC; Valderrábano F
    Nephron; 1998; 78(2):228-9. PubMed ID: 9496746
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
    Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
    Thromb Haemost; 2015 Apr; 113(4):719-27. PubMed ID: 25566930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delirium associated with acyclovir treatment in a patient with renal failure.
    Revankar SG; Applegate AL; Markovitz DM
    Clin Infect Dis; 1995 Aug; 21(2):435-6. PubMed ID: 8562758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurotoxicity induced by the recommended acyclovir dosing in a dialysis patient with herpes zoster: A case letter.
    Kageyama R; Hashizume H
    J Dermatol; 2016 Mar; 43(3):339-40. PubMed ID: 26589129
    [No Abstract]   [Full Text] [Related]  

  • 11. Neurotoxicity of acyclovir in patients with end-stage renal failure treated with continuous ambulatory peritoneal dialysis.
    Davenport A; Goel S; Mackenzie JC
    Am J Kidney Dis; 1992 Dec; 20(6):647-9. PubMed ID: 1462997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of valaciclovir dosage reduction in continuous ambulatory peritoneal dialysis patients.
    Stathoulopoulou F; Dhillon S; Thodis H; Stathakis C; Vargemezis V
    Nephron; 2002 May; 91(1):164-6. PubMed ID: 12021536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acyclovir Neurotoxicity in a Peritoneal Dialysis Patient: Report of a Case and Review of the Pharmacokinetics of Acyclovir.
    Sadjadi SA; Regmi S; Chau T
    Am J Case Rep; 2018 Dec; 19():1459-1462. PubMed ID: 30531673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal administration of acyclovir in patients receiving continuous ambulatory peritoneal dialysis.
    Burgess ED; Gill MJ
    J Clin Pharmacol; 1990 Nov; 30(11):997-1000. PubMed ID: 2243158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case Report of Neurotoxicity After Prolonged Doses of Acyclovir in a Patient With Renal Dysfunction.
    Umoru GO; Shah PJ; Tariq F
    J Pharm Pract; 2020 Apr; 33(2):217-221. PubMed ID: 30669921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acyclovir-induced neuropsychosis successfully recovered after immediate hemodialysis in an end-stage renal disease patient.
    Yang HH; Hsiao YP; Shih HC; Yang JH
    Int J Dermatol; 2007 Aug; 46(8):883-4. PubMed ID: 17651180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acyclovir-Induced Neurotoxicity: A Case Report and Review of Literature.
    Chowdhury MA; Derar N; Hasan S; Hinch B; Ratnam S; Assaly R
    Am J Ther; 2016; 23(3):e941-3. PubMed ID: 24942005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced encephalopathy secondary to non renal dosing of common medications in Two dialysis patients.
    Onuigbo MA; Nye D; Iloanya PC
    Adv Perit Dial; 2009; 25():89-91. PubMed ID: 19886325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabigatran treatment simulation in patients undergoing maintenance haemodialysis.
    Liesenfeld KH; Clemens A; Kreuzer J; Brueckmann M; Schulze F
    Thromb Haemost; 2016 Mar; 115(3):562-9. PubMed ID: 26467062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acyclovir-associated encephalopathy in haemodialysis.
    Peces R; de la Torre M; Alcázar R
    Nephrol Dial Transplant; 1996 Apr; 11(4):752. PubMed ID: 8671884
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.